New medical chief at Acceleron

Acceleron Pharma, a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, announced the appointment of Robert K. Zeldin, M.D., as Chief Medical Officer (CMO). Dr. Zeldin brings to Acceleron more than two decades of clinical, regulatory and industry experience, most recently serving as CMO of Belgium-based Ablynx NV.

"Robert has built an impressive career, holding a variety of leadership positions across clinical development, regulatory, and medical affairs functions," said Habib Dable, Chief Executive Officer of Acceleron. "He’s joining us at a critical time for the company as we advance our lead product candidate, luspatercept, in multiple hematologic indications. Moreover, we have ongoing Phase 2 programs with our key, wholly-owned pipeline assets in neuromuscular and pulmonary diseases. Robert’s breadth and depth of experience should prove immensely valuable in executing on our clinical development goals."

As a member of the Executive Committee at Ablynx, Dr. Zeldin contributed to the development and implementation of the overall corporate strategy. He was responsible for the Medical, Regulatory, Pharmacovigilance, Clinical Operations, Biostatistics, and Data Management functions and led a team of 60. He joined Ablynx from French pharmaceutical firm Stallergenes SA, where he was Senior Vice President and Head of Global Clinical Development. Earlier, he worked for five years at Novartis Pharmaceuticals, the final three as Vice President and U.S. Medical Franchise Head, Respiratory and Dermatology. Dr. Zeldin’s career in industry began at Merck, where he spent seven years in progressively strategic roles in worldwide regulatory affairs and clinical development, rising to the position of Senior Director of Clinical Development with responsibility for products in the respiratory, cardiovascular, and infectious disease therapeutic areas.

Dr. Zeldin succeeds longtime Acceleron CMO, Matthew Sherman, M.D., who earlier this year announced his planned retirement. Dr. Sherman will remain on staff until the anticipated mid-2018 release of topline Phase 3 data from the BELIEVE trial of luspatercept in beta-thalassemia patients, and will then serve in an advisory capacity for one year thereafter.

--------------------------------------------------------------------------------------------------------------------------------------------------

Editor's Note:

To apply for becoming a contributor of en-CPhI.Cn, 

welcome to send your CV and sample works to us, 

Email: Julia.Zhang@ubmsinoexpo.com.